The Hyperoxic-Hypoxic Paradox: Why HBOT Works the Way It Does

When people first encounter hyperbaric oxygen therapy, the mechanism seems straightforward: breathe high-concentration oxygen under elevated pressure, deliver more oxygen to tissues, promote healing. That explanation is accurate as far as it goes. But it describes only what happens inside the chamber. It does not explain why the effects of HBOT persist for weeks or months after a course of treatment ends — or why the body responds to HBOT in ways that go far beyond simple oxygen delivery.

The answer lies in a phenomenon known as the hyperoxic-hypoxic paradox, or HHP. It is one of the most important concepts in modern hyperbaric medicine, and understanding it changes how you think about what HBOT actually does.

What the Hyperoxic-Hypoxic Paradox Is

The paradox can be stated simply: exposure to high levels of oxygen triggers the body to respond as though it is experiencing low levels of oxygen.

During an HBOT session, the patient breathes pure or near-pure oxygen at pressures typically between 1.5 and 2.4 atmospheres absolute (ATA). This produces a state of hyperoxia — oxygen levels in the blood and tissues that are dramatically higher than normal. Arterial oxygen partial pressure can rise from a baseline of around 100 mmHg to over 1,500 mmHg. Tissues that are chronically hypoxic — poorly perfused, damaged, or inflamed — receive oxygen they have been starved of.

But here is where the paradox emerges. When the session ends and the patient returns to normal atmospheric conditions, the body experiences a relative drop in oxygen levels. Compared to the hyperoxic state inside the chamber, normal air feels, at a cellular level, like hypoxia. This fluctuation — the oscillation between high oxygen and relative low oxygen — is not merely a side effect of the treatment. It is, according to the research of Professor Shai Efrati and colleagues at the Sagol Center in Israel, the primary driver of HBOT's most significant and lasting biological effects.

The Cellular Mechanism

To understand why this matters, it helps to understand how cells respond to oxygen fluctuations.

The master regulator of the cellular response to low oxygen is a protein called hypoxia-inducible factor 1-alpha, or HIF-1alpha. Under normal oxygen conditions, HIF-1alpha is continuously produced and continuously degraded — it barely accumulates. But when oxygen levels fall, degradation slows and HIF-1alpha accumulates rapidly. Once it reaches sufficient concentration, it acts as a transcription factor, switching on a cascade of genes involved in angiogenesis (the formation of new blood vessels), stem cell mobilisation, anti-inflammatory signalling, and tissue repair.

The hyperoxic-hypoxic paradox exploits this system. The sharp drop in relative oxygen at the end of each HBOT session triggers HIF-1alpha accumulation, activating the same repair cascade that the body uses in response to genuine hypoxia. The key difference is that this happens in a patient who is otherwise well-oxygenated — the repair signals are activated without the tissue damage that normally accompanies true hypoxia.

Alongside HIF-1alpha, the fluctuation also activates other repair-related pathways. Vascular endothelial growth factor (VEGF) — a key driver of angiogenesis — is upregulated. Reactive oxygen species (ROS), which at low levels act as signalling molecules rather than damaging agents, are transiently elevated and trigger antioxidant responses. Stem cells are mobilised from the bone marrow into the circulation. Inflammatory cytokines are modulated.

The result is a coordinated biological response to perceived stress that promotes repair, regeneration, and adaptation — triggered not by damage, but by a carefully controlled oscillation in oxygen levels.

Why This Explains HBOT's Lasting Effects

The hyperoxic-hypoxic paradox resolves what has long been a puzzle in hyperbaric medicine: why do the effects of HBOT persist long after treatment ends?

If HBOT worked purely by delivering oxygen to hypoxic tissues, its effects would be expected to diminish once the treatment stopped and tissue oxygen levels returned to baseline. But clinical trials consistently show that improvements in neurological function, wound healing, cognitive performance, and other outcomes continue to develop after a course of treatment is complete — and in some cases are more pronounced at follow-up assessments than immediately after the final session.

This is consistent with what the HHP mechanism predicts. The biological processes activated by the hyperoxic-hypoxic oscillation — angiogenesis, neuroplasticity, stem cell activity — are not instantaneous. New blood vessels take time to form and mature. Neural connections take time to consolidate. The repair processes set in motion during a course of HBOT continue to unfold for weeks and months after the last session.

Efrati's group has documented this in their neurological trials. In the 2013 randomised controlled trial on HBOT in post-stroke patients, improvements in neurological function were observed not only at the end of the treatment period but continued to develop at the three-month follow-up. The same pattern has been observed in TBI and long COVID trials.

Why Protocol Design Matters

The hyperoxic-hypoxic paradox has direct implications for how HBOT protocols should be designed — and why the variation in protocols between facilities and conditions is not arbitrary.

For the HHP mechanism to operate effectively, the oscillation between hyperoxia and relative hypoxia needs to be sufficient to trigger the relevant cellular responses. This means the pressure and oxygen concentration during the session need to be high enough to produce genuine hyperoxia, and the return to normal conditions needs to be sharp enough to produce a meaningful relative drop.

This is one reason why low-pressure HBOT — sessions at 1.3 ATA with ambient air or modest oxygen concentrations — may produce different biological effects from high-pressure HBOT at 2.0 ATA with 100% oxygen. The hyperoxic state achieved at 1.3 ATA is less pronounced, and the relative drop at the end of the session is correspondingly smaller. Whether this is sufficient to activate the HHP mechanism to the same degree is a question that has not been fully resolved in the literature, but it is a legitimate basis for the clinical preference for higher pressures in neurological applications.

Session frequency also matters. The HHP mechanism depends on repeated oscillations — each session adds another cycle of hyperoxia and relative hypoxia, each cycle adding to the cumulative biological signal. This is why most research protocols involve 40 to 60 sessions rather than a handful of treatments. The repair processes being activated are dose-dependent, and the dose is measured not just in pressure and oxygen concentration but in the number of oscillation cycles delivered.

The interval between sessions may also be relevant. Some researchers have proposed that allowing sufficient time between sessions for the cellular response to develop — rather than compressing sessions into rapid succession — may optimise the cumulative effect. This is an area of ongoing investigation.

The Broader Significance

The hyperoxic-hypoxic paradox reframes HBOT from a simple oxygen delivery system into something more sophisticated: a controlled biological stressor that activates the body's own repair and regeneration machinery.

This framing has implications beyond hyperbaric medicine. It connects HBOT to a broader class of interventions — including intermittent hypoxia training, cold exposure, and certain forms of exercise — that work by exposing the body to controlled stress in order to trigger adaptive responses. The common thread is hormesis: the principle that low-level stress, applied in the right dose and pattern, produces beneficial adaptation.

What distinguishes HBOT within this class is the precision with which the stress can be controlled. Pressure, oxygen concentration, session duration, and frequency can all be adjusted to target specific biological mechanisms. This is why the protocol matters — and why the clinical decisions about which protocol to use for which patient and which condition belong with physicians who understand the underlying biology.

What This Means in Practice

For patients considering HBOT, the hyperoxic-hypoxic paradox is relevant in several ways.

It explains why a full course of treatment is necessary to achieve meaningful results. A handful of sessions will not produce the cumulative biological signal that drives angiogenesis, neuroplasticity, and stem cell mobilisation. The research protocols that have demonstrated clinical benefit have consistently involved 40 to 60 sessions.

It explains why the pressure and oxygen concentration used in a protocol matter, and why not all HBOT is equivalent. A facility offering sessions at 1.3 ATA with ambient air is delivering a different biological stimulus from one offering 2.0 ATA with 100% oxygen. Whether that difference matters for a given condition and patient is a clinical question — but it is a question worth asking.

And it explains why the effects of HBOT continue to develop after treatment ends. Patients and referring physicians who assess outcomes only at the end of the treatment period may be measuring before the full biological response has matured.

Understanding the mechanism does not replace clinical judgment. But it provides a framework for asking better questions — of facilities, of protocols, and of the evidence base for specific applications. That is the kind of informed navigation that leads to better outcomes.